TuHURA Biosciences stock price increases, once again complies with NASDAQ regulatory requirements

2026-02-27 20:02:44

Abstract generation in progress

Investing.com – TuHURA Biosciences Inc (NASDAQ:HURA) stock rose 7.4% on Friday after the company announced it once again met the minimum bid price requirement for Nasdaq.

The company received a written notification from Nasdaq Stock Market LLC on Wednesday confirming that it complies with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00. From February 10 to February 25, 2026, TuHURA’s common stock closed at $1.00 or higher for 11 consecutive trading days.

TuHURA Biosciences is a late-stage oncology immunotherapy company focused on developing treatments to overcome resistance to cancer immunotherapy.

The company is currently advancing patient recruitment for its Phase 3 accelerated approval trial of IFX-2.0 for first-line Merkel cell carcinoma. TuHURA is also preparing to launch a Phase 2 study of its VISTA inhibitory antibody TBS 2025 for relapsed/refractory NPM1-mutated acute myeloid leukemia.

James Bianco, Ph.D., President and CEO of TuHURA Biosciences, said, “We are pleased to once again fully meet Nasdaq’s listing standards and will continue to focus on advancing our pipeline.”

The company is also making progress toward preclinical proof of concept for its innovative immunomodulatory antibody-drug conjugate.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.